Theravance Biopharma (NASDAQ:TBPH) Price Target Cut to $9.00 by Analysts at TD Cowen

Theravance Biopharma (NASDAQ:TBPH) had its target price lowered by TD Cowen from $10.00 to $9.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a buy rating and set a $20.00 target price on shares of Theravance Biopharma in a report on Wednesday, May 29th. BTIG Research initiated coverage on shares of Theravance Biopharma in a research note on Friday, April 12th. They set a buy rating and a $21.00 price objective on the stock. StockNews.com downgraded shares of Theravance Biopharma from a buy rating to a hold rating in a research note on Thursday, August 1st. Finally, SVB Leerink downgraded Theravance Biopharma from an outperform rating to a market perform rating and cut their price target for the stock from $15.00 to $10.00 in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Hold and an average price target of $13.75.

Theravance Biopharma Price Performance

Shares of TBPH opened at $7.68 on Tuesday. Theravance Biopharma has a twelve month low of $7.62 and a twelve month high of $11.71. The firm has a fifty day simple moving average of $9.04 and a two-hundred day simple moving average of $9.08.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 20.63% and a negative net margin of 73.61%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same quarter in the prior year, the company posted ($0.28) earnings per share. On average, equities research analysts predict that Theravance Biopharma will post -0.42 EPS for the current year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gerber LLC purchased a new position in shares of Theravance Biopharma in the 4th quarter worth $112,000. Wellington Management Group LLP lifted its stake in shares of Theravance Biopharma by 68.0% in the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after purchasing an additional 116,164 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Theravance Biopharma by 16.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 7,509 shares during the period. Bleakley Financial Group LLC purchased a new stake in Theravance Biopharma during the fourth quarter valued at approximately $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Theravance Biopharma by 31.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 2,227 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.